Is peritoneal dialysis a suitable renal replacement therapy in autosomal dominant polycystic kidney disease?

2009 ◽  
Vol 5 (3) ◽  
pp. 122-123 ◽  
Author(s):  
Eric Goffin ◽  
Yves Pirson
Keyword(s):  
Peritoneal Dialysis ◽  
Renal Replacement Therapy ◽  
Kidney Disease ◽  
Replacement Therapy ◽  
Polycystic Kidney Disease ◽  
Autosomal Dominant ◽  
Polycystic Kidney ◽  
Autosomal Dominant Polycystic Kidney

scholarly journals Demographic, diagnostic and therapeutic characteristics of autosomal dominant polycystic kidney disease in Ghana

2021 ◽  
Vol 22 (1) ◽  
Author(s):  
Perditer Okyere ◽  
Richard K.D. Ephraim ◽  
Isaac Okyere ◽  
Joseph Attakorah ◽  
Dorcas Serwaa ◽  
...  
Keyword(s):  
Renal Replacement Therapy ◽  
Kidney Disease ◽  
Replacement Therapy ◽  
Polycystic Kidney Disease ◽  
Clinical Features ◽  
Conservative Therapy ◽  
Autosomal Dominant ◽  
Polycystic Kidney ◽  
Autosomal Dominant Polycystic Kidney ◽  
Tract Infections

AbstractBackgroundAutosomal Dominant Polycystic Kidney Disease (ADPKD) is the commonest of the hereditary kidney diseases and mostly ensues in utero with signs delayed until after several decades. This study assessed the demographic, diagnostic (clinical and biochemical features) and therapeutic patterns among ADPKD patients who attended the nephrology unit of Komfo Anokye Teaching Hospital (KATH) from 2007 to 2018.MethodsThis cross-sectional retrospective analysis of ADPKD patient records was conducted at the nephrology unit of KATH in October 2020. The records of 82 ADPKD was used for this study. Demographic, clinical, biochemical, ultrasonographic and therapeutic data was obtained, organized and analyzed with Statistical Package for the Social Sciences (SPSS).ResultsADPKD was most prevalent in people within the ages of 31–40 years (25.6 %), with a male (52.4 %) preponderance. The most common clinical features presented were flank pain (30.5 %) and bipedal swelling (18.3 %). Hypertension (42.7 %), urinary tract infections (UTIs) (19.5 %), and anemia (13.4 %) were the most common complications reported. Average level of HDL-c was higher in females (1.7) than in males (1.2) (p = 0.001). Hematuria (34 %) and proteinuria (66 %) were among the biochemical derangements presented. About 81.7 % had CKD at diagnosis with the majority in stages 1 (27.0 %), 3(23.2 %) and 5 (20.3 %). Poor corticomedullary differentiation was observed in 90.2 % of participants and increased echogenicity was observed in 89.0 % of the participants. Estimated GFR (eGFR) correlated positively with echotexture (r = 0.320,p = 0.005) and negatively with CMD (r= -0.303,p = 0.008). About 95.1 % of patients were on conservative therapy including: 73.2 %, 52.4 %, 22.0 %, 13.4 %, 8.5 % on Irebesartan/Lisinopril, Nifecard XL, Hydralazine, Methyldopa and Bisoprolol respectively for hypertension; 26.8 and 3.7 % on Gliclazide and Metformin respectively for Type 2 diabetes mellitus; 25.6 %, 24.4 and 18.3 % on CaCO3, fersolate and folic acid respectively as nutrient supplements with 4.9 % of participants on renal replacement therapy (RRT).ConclusionsADPKD occurs in people aged ≥ 31 years with a higher male preponderance. Clinical features include flank and abdominal pain, bipedal swelling, headache, amongst others. Uremia, hematuria, proteinuria, decreased eGFR, were the common biochemical derangements reported with higher severity detected in men. The therapeutic interventions mostly involved conservative therapy to manage symptoms and other comorbid conditions and rarely renal replacement therapy (RRT).

scholarly journals High Serum Phosphate Level as a Risk Factor to Determine Renal Prognosis in Autosomal Dominant Polycystic Kidney Disease: A Retrospective Study

Medicines ◽  
2020 ◽  
Vol 7 (3) ◽  
pp. 13
Author(s):  
Masayo Sato ◽  
Hiroshi Kataoka ◽  
Yusuke Ushio ◽  
Shun Manabe ◽  
Saki Watanabe ◽  
...  
Keyword(s):  
Renal Replacement Therapy ◽  
Kidney Disease ◽  
Replacement Therapy ◽  
Polycystic Kidney Disease ◽  
Autosomal Dominant ◽  
Kidney Diseases ◽  
Serum Phosphate ◽  
Serum Phosphate Level ◽  
Polycystic Kidney ◽  
Autosomal Dominant Polycystic Kidney

Background: Serum phosphate levels, which are associated with the progression of renal dysfunction in chronic kidney disease, in patients with autosomal dominant polycystic kidney disease (ADPKD) are lower than those in patients with other kidney diseases. However, their role in ADPKD remains unclear. This study aimed to determine whether serum phosphate levels could have an association with renal prognoses among patients with ADPKD. Methods: In total, 55 patients with PKD1 or PKD2 mutations but not undergoing dialysis were evaluated. Data regarding serum phosphate levels were collected, and Cox regression analyses were used to calculate hazard ratios (HRs) with renal replacement therapy as the endpoint. Results: The median (quartile 1; quartile 3) serum phosphate concentration was 3.4 (3.1; 3.9) mg/dL, and the estimated glomerular filtration rate (eGFR) was 39.5 (17.6; 65.7) mL/min/1.73 m2. The multivariate analysis that included age, PKD1 mutation, eGFR, urinary protein excretion, hyperuricemia, and serum phosphate determined that eGFR (HR, 0.82; 95% confidence interval (CI), 0.74–0.90; p < 0.0001) and serum phosphate (HR, 6.78; 95% CI, 1.94–34.02; p = 0.0021) were independently associated with renal replacement therapy. Conclusions: We found that serum phosphate levels were significantly associated with poor renal prognoses in patients with ADPKD.

scholarly journals Age at Renal Replacement Therapy in Autosomal Dominant Polycystic Kidney Disease

Nephron ◽  
1996 ◽  
Vol 74 (3) ◽  
pp. 620-620 ◽  
Author(s):  
Ana Gonzalo ◽  
Araceli Gallego ◽  
Ana Tato ◽  
Joaquin Ortu&ntilde;o
Keyword(s):  
Renal Replacement Therapy ◽  
Kidney Disease ◽  
Replacement Therapy ◽  
Polycystic Kidney Disease ◽  
Autosomal Dominant ◽  
Polycystic Kidney ◽  
Autosomal Dominant Polycystic Kidney
Sign in / Sign up

Export Citation Format

Share Document